Thursday, February 8, 2007 - 18:30

Innate Pharma SA announced today that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans.

AttachmentSize
PR in english83.41 KB
CP en français80.53 KB